The clinical picture of metabolic syndrome: An update on this complex of conditions and risk factors

Postgraduate Medicine

Volumn 116, Issue 1, 2004, Pages 30-38

  Doelle, Gregory C ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIFENE CITRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MILOPHENE; NICOTINIC ACID; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; STATIN; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LOW FAT DIET; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SODIUM RESTRICTION; STOMACH BYPASS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 3042723900     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2004.07.1549     Document Type: Conference Paper

References (26)

1. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37(12):1595-607
2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111). JAMA 2001;285(19): 2486-97
3. Bonora E, Zavaroni I, Alpi O, et el. Relationship between blood pressure and plasma insulin in non-obese and obese non-diabetic subjects. Diabetologia 1987;30(9):719-23
4. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320(11):702-6
5. Beatty OL, Harper R, Sheridan B, et al. Insulin resistance in offspring of hypertensive parents. Br Med J 1993;307(6896):92-6
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356-9
7. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21(6):697-738
8. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88(10):4525-32
9. Natural history of myocardial infarction in the Coronary Drug Project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group. Am J Cardiol 1978;42(3):489-98
10. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Eng J Med 1999;341(6):410-8
11. Voors AW, Webber LS, Frerichs RR, et al. Body height and body mass as determinants of basal blood pressure in children - the Bogalusa Heart Study. Am J Epidemiol 1977;106(2):101-8
12. Havlik RJ, Hubert HB, Fabsitz RR, et al. Weight and hypertension. Ann Intern Med 1983;98(5 Pt 2):855-9
13. Reisin E, Abel R, Modan M, et al. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978;298(1)1-6
14. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72 [Erratum, JAMA 2003;290(2):197]
15. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72 [Erratum, JAMA 2003;290(2):197]
16. Pasternak RC. The ALLHAT lipid lowering trial-less is less. JAMA 2002;288(23):3042-4
17. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94(3):1172-9
18. Anderson EA, Hoffman RP, Balon TW, et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991;87(6):2246-52
19. Skott P, Vaag A, Bruun NE, et al. Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance. Diabetologia 1991;34(4):275-81
20. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Eng J Med 2002;346(6):393-403
21. Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28(1):99-109
22. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br Med J 2003;327(7421):951-3
23. Saad MF, Knowler WC, Pettitt DJ, et al. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 1988;319(23):1500-6
24. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22(6):920-4
25. Hanefeld M, Koehler C, Henkel E, et al. Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes. Diabet Med 2000;17(12):835-40
26. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25(7):1135-41